Zenas BioPharma hits record high as brokerages raise PT

Zenas BioPharma

09/10/2025 17:22

** U.S. drug developer Zenas BioPharma's ZBIO.O shares rise 6.9% to record high of $27.68

** Two brokerages raise PT on ZBIO

** ZBIO signed a licensing deal worth over $2 bln with China's InnoCare 688428.SS for multiple sclerosis drug orelabrutinib on Wednesday

** Wedbush raises PT to $40 from $35

** "With an increasingly diversified pipeline, favorable licensing/royalty deals, and now two programs in phase 3 development, we would be buyers ahead of upcoming data read-outs" - Wedbush

** Jefferies raises ZBIO's PT to $43 from $35

** Think InnoCare deal is a smart move, as ZBIO now has two late-stage assets across five indications - Jefferies

** Up to last close, ZBIO's stock had risen more than threefold YTD

(Reporting by Juby Babu in Mexico City)

((Juby.Babu@thomsonreuters.com;))